3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
9
Prostatic Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma
2
Hemorrhage
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thromboembolism
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Cyst
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Neurotoxicity Syndromes
1
Myofibroma
1
Multiple Myeloma
1
Metabolic Diseases
1
Melanoma
1
Interventions
Paclitaxel
23
Carboplatin
22
Capecitabine
18
Gemcitabine
16
130-nm albumin-bound paclitaxel
16
pembrolizumab
14
Cyclophosphamide
12
atezolizumab
9
Epirubicin
9
sacituzumab govitecan
8
Albumin-Bound Paclitaxel
8
eribulin
6
Vinorelbine
6
Drug Therapy
6
Doxorubicin
6
camrelizumab
4
Docetaxel
4
Cisplatin
4
Injections
3
pegfilgrastim
2
olaparib
2
famitinib
2
Filgrastim
2
Everolimus
2
veliparib
1
trilaciclib
1
toripalimab
1
taxane
1
niraparib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Triple Negative Breast Neoplasms
×
Saline Solution
×
Clear all
NCT04799249
2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3
Completed
194 enrolled